Medical devices, healthcare technology and the business of care
PMA approval · P190018

Clareon Aspheric Hydrophobic Acrylic Intraocular Lens (IOL), Clareon Toric Aspheric Hydrophobic Acrylic Intraocular Lens

Alcon Laboratories, LLC · Decision date Jan 7, 2020

FDA DECISIONP190018

What did the FDA approve?

FDA records P190018 as an original PMA application. The recorded decision is approval, dated Jan 7, 2020.

FDA approval order statement

Approval for the Clareon and Clareon Toric Aspheric Hydrophobic Acrylic Intraocular Lens (IOL).Clareon Aspheric Hydrophobic Acrylic Intraocular Lens (IOL):The Clareon Aspheric Hydrophobic Acrylic Intraocular Lens (IOL) is indicated for primary implantation in the capsular bag in the posterior chamber of the eye for the visual correction of aphakia in adult patients in whom a cataractous lens has been removed. Clareon Toric Aspheric Hydrophobic Acrylic Intraocular Lens (IOL):The Clareon Toric Aspheric Hydrophobic Acrylic Intraocular Lenses (IOLs) are indicated for primary implantation in the capsular bag in the posterior chamber of the eye for visual correction of aphakia and pre-existing corneal astigmatism to reduce residual refractive cylinder and improve uncorrected distance vision in adult patients in whom a cataractous lens has been removed. Clareon Aspheric Hydrophobic Acrylic Intraocular Lens (IOL) with the AutonoMe Pre-loaded Delivery System:The Clareon Aspheric Hydrophobic Acrylic Intraocular Lens (IOL) is indicated for primary implantation in the capsular bag in the posterior chamber of the eye for the visual correction of aphakia in adult patients in whom a cataractous lens has been removed. Clareon Toric Aspheric Hydrophobic Acrylic Intraocular Lens (IOL) with the AutonoMe Pre-loaded Delivery System:The Clareon Toric Aspheric Hydrophobic Acrylic Intraocular Lenses (IOLs) are indicated for primary implantation in the capsular bag in the posterior chamber of the eye for visual correction of aphakia and pre-existing corneal astigmatism to reduce residual refractive cylinder and improve uncorrected distance vision in adult patients in whom a cataractous lens has been removed.
Regulatory pathway
Original PMA
Clinical specialty
Ophthalmic
Decision date
Jan 7, 2020

FDA source record

Regulatory record facts

Identifier
P190018
Regulatory pathway
Premarket approval application
Product code
HQL
Decision code
APPR
Decision date
Jan 7, 2020
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: intraocular lens.

Product code
HQL
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P190018 received

    Application receipt date recorded by FDA.

  2. P190018 · FDA decision

    APPR

  3. P190018/S050 · Related supplement

    Clareon Vivity Pro Extended Vision IOLs

Timeline entries are records held by MedtechLedger for P190018. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P190018

Product / regulatory recordCompanyPathwayDecision dateSource
Alcon Laboratories, LLCPMA supplementOct 30, 2026FDA

Explore the linked device profile

Other records with product code HQL

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Alcon Laboratories, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6201 S. Fwy., Fort Worth, TX, 76134

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records